Food and Drug Administration (FDA) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Antagonism of the Platelet-Activating Factor Pathway Mitigates Inflammatory Adverse Events Driven by Anti-erythrocyte Antibody Therapy in Mice
J Immunol. 2024 Mar 20:ji2300638. doi: 10.4049/jimmunol.2300638. Online ahead of print.ABSTRACTImmune thrombocytopenia (ITP) is an autoimmune disease characterized by low platelet counts primarily due to antiplatelet autoantibodies. Anti-D is a donor-derived polyclonal Ab against the rhesus D Ag on erythrocytes used to treat ITP. Unfortunately, adverse inflammatory/hypersensitivity reactions and a Food and Drug Administration-issued black box warning have limited its clinical use. This underscores the imperative to understand the inflammatory pathway associated with anti-erythrocyte Ab-based therapies. TER119 is an erythro...
Source: Journal of Immunology - March 20, 2024 Category: Allergy & Immunology Authors: Kevin Doyoon Won Lazaro Gil Gonzalez Yoelys Cruz-Leal Alequis Pavon Oro Alan H Lazarus Source Type: research

Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy
Clin Ther. 2024 Mar 19:S0149-2918(24)00062-6. doi: 10.1016/j.clinthera.2024.02.007. Online ahead of print.ABSTRACTPURPOSE: Hypertrophic cardiomyopathy (HCM) is an under-recognized genetic cardiac disorder affecting the muscles and contractility of the heart, which in turn can result in heart failure symptoms, arrhythmia, and sudden cardiac death. Previously, pharmacotherapy options for HCM were not disease-specific, often poorly tolerated, and overall inadequate for optimal management. This narrative review discusses the pharmacology of the novel drug mavacamten, the clinical trials supporting its use, and considerations f...
Source: Clinical Therapeutics - March 20, 2024 Category: Drugs & Pharmacology Authors: J Chase Cole Samantha F Benvie Marci DeLosSantos Source Type: research

Bacteroides and NAFLD: pathophysiology and therapy
Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic liver condition observed globally, with the potential to progress to non-alcoholic steatohepatitis (NASH), cirrhosis, and even hepatocellular carcinoma. Currently, the US Food and Drug Administration (FDA) has not approved any drugs for the treatment of NAFLD. NAFLD is characterized by histopathological abnormalities in the liver, such as lipid accumulation, steatosis, hepatic balloon degeneration, and inflammation. Dysbiosis of the gut microbiota and its metabolites significantly contribute to the initiation and advancement of NAFLD. Bacteroides, a potential...
Source: Frontiers in Microbiology - March 20, 2024 Category: Microbiology Source Type: research

Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents
Expert Rev Neurother. 2024 Mar 19:1-13. doi: 10.1080/14737175.2024.2327533. Online ahead of print.ABSTRACTINTRODUCTION: Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention and/or hyperactivity and impulsivity. Viloxazine extended-release (ER) capsules (Qelbree®) is a US Food and Drug Administration-approved nonstimulant treatment option for children, adolescents, and adults with ADHD.AREAS COVERED: This review manuscript summarizes the neurobiology of ADHD and currently available treatment options before discussing viloxazine pharmacology, efficacy, safety, and tol...
Source: Expert Review of Neurotherapeutics - March 19, 2024 Category: Neurology Authors: Vladimir Maletic Gregory W Mattingly Jami Earnest Source Type: research

Riboflavin protects against pancreatic cancer metastasis by targeting TGF- β receptor 1
Bioorg Chem. 2024 Mar 16;146:107274. doi: 10.1016/j.bioorg.2024.107274. Online ahead of print.ABSTRACTThe inhibition of transforming growth factor-β1 (TGF-β1) signaling by targeting TGF-β receptor 1 (TβR1) has been considered as an ideal approach for the prevention of pancreatic cancer metastasis. Utilizing a pharmacophore model for TβR1 inhibitors, candidate compounds with the potential TβR1 binding ability were screened from the U.S. Food and Drug Administration (FDA) database, and riboflavin (RF) with a highest fit value was chosen to investigate its binding ability to TβR1 and effect on TGF-β1 signaling in panc...
Source: Bioorganic Chemistry - March 19, 2024 Category: Chemistry Authors: Juanping Zhao Xiaofeng Liu Xinxin Jin Tianyi Dong Xiong Gao Jian Wang Yanchun Li Enlong Ma Source Type: research